Ochsner Health System

Ochsner's venture-investment activities fall under Ochsner Ventures, which is governed by the health system's senior executive leadership team. Pete November, CEO, has oversight of strategic capital allocation. Day-to-day investment operations are managed by an internal team that reports through the chief strategy officer and evaluates deals against clinical integration criteria. The system does not outsource its venture function to a third-party manager.

Ochsner's primary sourcing advantage is its own clinical network. The system identifies emerging companies through its physician-led innovation programs, pilot partnerships, and its own IT procurement pipeline. Ochsner also co-invests alongside health-system peers and maintains relationships with specialist health-tech venture funds. Because Ochsner can offer a multi-hospital testing environment, startups frequently approach the system before raising institutional rounds.

Ochsner Ventures operates as an in-house strategic investment unit funded by the health system's balance sheet. It is not a standalone fund with external limited partners. This structure lets Ochsner make investment decisions based on clinical value and strategic fit rather than fund-return timelines. Investments are held on the system's books as long-term assets.

Ochsner's venture activity is predominantly direct, reflecting its goal of deploying portfolio-company technology inside its own operations. The system may also evaluate selective fund commitments, particularly to vehicles led by experienced health-tech managers with deep domain expertise, but direct strategic investments are the core model.

Venture capital investments are segregated from clinical operating funds and overseen by a dedicated investment governance committee within the system's executive leadership. Philanthropic activities run through a separate Ochsner Health Foundation. The fitness center chain and real-estate holdings are managed as distinct operating businesses, with their own P&L structures, under the overall system umbrella.

Ochsner Ventures targets seed-to-growth-stage companies. It looks for post-revenue startups that have a working product ready for clinical piloting within Ochsner's network. The system occasionally participates in later-stage rounds for companies that have already demonstrated clinical efficacy inside its hospitals and are seeking scale capital.

Ochsner's venture mandate is explicitly tied to technologies that improve clinical outcomes or operational efficiency within a hospital system. The system does not invest in pure biotechnology drug development, medical-device hardware requiring FDA premarket approval, or sectors outside healthcare delivery, as those lie beyond its strategic integration thesis.